Amicus Therapeutics Inc

Amicus Therapeutics — Technical Presentation (February 2020)

41 slides from Amicus Therapeutics's technical presentation, Feb 12, 2020

  1. Slide 1: Perspectives on Pompe: Progress, Persistence and Passion

    Perspectives on Pompe: Progress, Persistence and Passion February 12, 2020

  2. Slide 2: Forward-Looking Statements

    2 Forward-Looking Statements This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 relating to scientific theories regarding our product candidate and to preclinical and clinical development of our product candidates. The i

  3. Slide 3: Importance of Properly Glycosylated rhGAA for Treating Pompe Disease

    Importance of Properly Glycosylated rhGAA for Treating Pompe Disease Hung Do, Ph.D., Chief Science Officer “We encourage and embrace constant innovation” - Amicus Belief Statement

  4. Slide 4: Carbohydrates Are Critical for Sorting and Transporting Proteins

    Importance of Properly Glycosylated rhGAA for Treating Pompe Disease 4 Carbohydrates Are Critical for Sorting and Transporting Proteins From Within and Outside of Cells • ALL lysosomal, ER, Golgi, secretory (e.g., antibodies and clotting factors), membrane, and peroxisomal and most mitochondrial pro

  5. Slide 5: N-Linked Carbohydrate Processing is Complicated and Difficult to Regulate

    Importance of Properly Glycosylated rhGAA for Treating Pompe Disease 5 N-Linked Carbohydrate Processing is Complicated and Extremely Difficult to Regulate in Production Cells • Vast majority of proteins synthesized in ER are modified with asparagine (N)-linked carbohydrates (N-glycans) during protei

  6. Slide 6: GAA Is Inherently Poorly Phosphorylated in Cells

    Importance of Properly Glycosylated rhGAA for Treating Pompe Disease 6 GAA Is Inherently Poorly Phosphorylated in Cells Relative Binding to M6P Receptor Liu et al., 2017 Alglucosidase alfa • rhGAA is among a group of lysosomal enzymes that are inherently poorly phosphorylated – Phosphotransferase is

  7. Slide 7: Only Tiny Amounts of rhGAA Reach Intended Muscles

    Importance of Properly Glycosylated rhGAA for Treating Pompe Disease 7 Only Tiny Amounts of rhGAA from Circulation Actually Reach Intended Muscles Do et al., 2019 Biodistribution of rhGAA ERT to intended muscles is very poor which necessitates highly efficient cellular uptake mechanisms Endothelial

  8. Slide 8: N-Glycan Structures Dictate Cellular Uptake of ERTs

    Importance of Properly Glycosylated rhGAA for Treating Pompe Disease 8 N-Glycan Structures Dictate Cellular Uptake of ERTs in Target Cells Adapted from Tong et al., 1989 Soluble lysosomal enzymes require M6P for cellular uptake; bis-phosphorylated N-glycans would be needed for uptake at low enzyme c

  9. Slide 9: ATB200: Optimized rhGAA with Higher M6P Receptor Binding Affinity

    Importance of Properly Glycosylated rhGAA for Treating Pompe Disease 9 ATB200: Amicus’ Optimized rhGAA ERT Has Substantially Higher Binding Affinity to M6P Receptor for Improved Cellular Uptake M6P Receptor Chromatography ATB200: Amicus’ Next-Generation rhGAA ERT for Pompe Disease Alglucosidase alfa

  10. Slide 10: Enhanced Cellular Uptake of AT-GAA Improves Glycogen Reduction

    Importance of Properly Glycosylated rhGAA for Treating Pompe Disease 10 Enhanced Cellular Uptake of AT-GAA Leads to Much Improved Glycogen Reduction and Reversal of Muscle Pathology in Preclinical Models - Xu et al., 2019 Myofiber Structure Analysis by SHG/2PEF Microscopy ERT concentration range in

  11. Slide 11: NeoGAA Therapeutics

    NeoGAA Therapeutics

  12. Slide 12: Key Reported Features of NeoGAA

    12 Key Reported Features of NeoGAA Zhu et al., 2009 Chemical Structure of NeoGlycan Schematic of Chemical Conjugation Approach Zhu et al., 2009 • NeoGAA approach relies upon the chemical conjugation of synthetic M6P-bearing carbohydrate structure (Neo- glycan) onto existing N-glycans of alglucosidas

  13. Slide 13: NeoGAA's Approach for Increasing M6P Levels on Alglucosidase Alfa

    13 Neo-GAA’s Approach for Increasing M6P Levels on Alglucosidase Alfa by Attaching Synthetic Carbohydrate Structure - Zhu et al. 2009 Resultant stable oxime chemical bond is unnatural and cannot be hydrolyzed by enzymes within cells which would negatively impact GAA processing Chemically oxidized te

  14. Slide 14: GAA Processing in Lysosomes is Required for Optimal Glycogen Hydrolysis

    14 GAA Processing in Lysosomes is Required for Optimal Glycogen Hydrolysis Moreland et al. (2012) Gene 491 25-30 Wisselaar et al. (1993) J. Biol. Chem. 268(3) 2223-2231

  15. Slide 15: Fully Processed GAA and Debranching Enzyme Required for Glycogen Catabolism

    15 Fully Processed GAA and Debranching Enzyme Are Required for Efficient Glycogen Catabolism in Lysosomes Glycogen debrancher enzyme (Cori-Forbes disease; GSD type III) acid α-glucosidase (GAA) Public domain images (Pompe disease; GSD type II) from WikiMedia Commons Glycogen • Glycogen is a large po

  16. Slide 16: ATB200-02 Clinical Outcome in Naive Patients - Behind the Data

    ATB200-02 Clinical Outcome in 4 Naive Patients - Behind the Data Dr Drago Bratkovic MBBS FRACP Women’s and Children’s Hospital, Adelaide, South Australia

  17. Slide 17: Overview

    Overview • ATB200-02 Trial Protocol Overview • Combined Data • Individualised Data of Naive Patients • 6MWT, FVC, GSGC (Gait, Stair, Gower's, Chair) • Patient Reported Outcomes - Fatigue Severity Score • Clinical Description • Summary

  18. Slide 18: ATB200-02 Study Design (NCT02675465)

    ATB200-02 Study Design (NCT02675465) « Phase 1/2 study to evaluate safety, tolerability, PK, PD, and efficacy of ATB200/AT2221 in adults with Pompe disease? 18-Week Primary Treatment Period With Long-Term Extension Stage 1 (6 wks) age 2 (12 wks { : (2 yrs, ongoing) ATB200 single-dose 0 2 N f 5 mg/kg

  19. Slide 19: Baseline Characteristics

    Baseline Characteristics Cohort 1 Cohort 2 Cohort 3 ERT-Switch ERT-Switch? ERT-Naive _ERT-Switct (2-6 yrs on ERT) | Non-ambulatory (27 yrs on ERT) n=11 n=6 n=5 n=6 Age, years, mean (min, max) | 49.4 (28, 66) 41.5 (18, 57) 49.4 (24, 65) Sex, M:F | 9:2 4:2 1:4 40.8 (20, 65) 2:4 Time on alglucosidase a

  20. Slide 20: 6-Minute Walk Test

    6-Minute Walk Test Cohorts 1 and 3 Baseline (meters) 397.2 (96.8) | 107] +23.9(52.2) | 108] +42.2 (46.5) ERT-Naive 399.5 (83.5) 5 +41.8 (29.4) 5 +63.1 (29.1) +60.7 (36.5) | 5 | = 6MWT increased in 7/10, 9/10, and 8/9 ERT-switch patients at Months 6, 12, and 24, respectively ™ 6MWT increased in 5/5,

  21. Slide 21: Sitting Forced Vital Capacity (FVC, % Predicted)

    Sitting Forced Vital Capacity (FVC, % Predicted) 52.6 (14.7) -1.2 (4.0) -3.0 (6.0) +0.9 (4.9) 53.2 (20.1) +4.4 (5.6) +4.6 (8.8) esta ™ FVC was stable or increased in 5/8 ERT-switch patients at Month 24 (2-6 yrs on ERT); MIP was stable and MEP increased ™ FVC was stable or increased in 5/5 ERT-naive

  22. Slide 22: GSGC Combination Measure

    GSGC Combination of: • Gait (G) • Climbing stairs (S) • Gower’s maneuver (G) • Arising from a chair (C) Quality of the activity is scored by an observer and timed Measure of day to day activities Scored as the sum of the scores • Lower the better • Maximum 27, Minimum 4

  23. Slide 23: GSGC Score Before and After ERT

    sec ° TF Gait Stairs Gower Chair Score eS ee a) ne 34 FIGURE 1. Results of the GSGC score before and after 1 year of ERT. TO = baseline. T12 = 12 months. The functional tests are timed in seconds, while the score expresses the sum of points of each test. Asterisks show significance P < 0.05. oNna@ a

  24. Slide 24: Timed Motor Function Tests

    Timed Motor Function Tests Baseline, Change From Baseline, mean (SD mean(SD) | Month6 | Month 12 | Month 24 EE eee ee Timed UpandGo, sec. 10.5(6.6) | -1.8(3.5) | -1.5(2.8) | —_-0.7 (2.5) GSGC Score | 12.6(4.8) | +0.1 (3.9) | -0.3(4.1) | 0.1 (5.2) ones Timed UpandGo, sec. 9.4(2.3) | -1.0(1.1) | -0.3

  25. Slide 25: Fatigue Severity Scale

    Fatigue Severity Scale 7 point scale 9 questions Range 7 to 63 • Sometimes expressed as a mean of the 9 scores (1-7) • Lower the Better Validated and used in a number of neurological disorders including Pompe disease

  26. Slide 26: Fatigue Severity Scale Scores During ERT

    During ER’ Fatigue severity Scale Scores 2 ° To © ° 4 J °oo8 oo, ° ° ° gic ° 1 ° $ [29% 00 @ 8 7 6 8 4 3 2 -1StartERT1 2 3 4 5 6 7 8 Follow-up duration in years Fig. 1. The figure shows the change in Fatigue Severity-Scale scores (FSS) before and after the start of enzyme replacement therapy (ERT).

  27. Slide 27: Fatigue Severity Scale

    Fatigue Severity Scale Patient-Reported Outcome (PRO) Instrument Cohort Max score=63 -8.0 (10.7) -8.0 (6.5) 10°| -4.1 (8.6) |e +2.0(7.5) | 5°} -12.5 (10.0) 45.6 (14.7) | 5° ERT-Naive 39.2 (12.7) 5 | 5.2(11.7) | 5 | -7.2(75) | 5 ERT=enzyme replacement therapy; SD=standard deviation. 1. Grace J et al.

  28. Slide 28: Subject: Early 40s and mother of pre-teen children

    Subject 1 Early 40s and mother of 2 pre teen children Diagnosed 4 years prior to ATB200-02 Noticing gradual decline in motor function especially in last few Change at Change at Baseline years 12 months 24 months Unable to safely run and requiring support to get up stairs 6MWT (m) 480 94.6 78.2 Not o

  29. Slide 29: Subject: Mid 20s living at home with her mother

    Subject 2 Mid 20’s and living at home with her mother Diagnosed 5 years prior to study with issues getting up from a chair and increasing headaches. GP noticed a positive Gower’s Change at Change at Baseline sign 12 months 24 months Significant respiratory compromise 6MWT (m) 384.1 78.9 106.9 • BiPA

  30. Slide 30: Subject: Early 60s

    Subject 3 Early 60’s Symptomatic from 40’s similar to her sister who was diagnosed at this age. Change at Change at Baseline Put off testing until she started having problems with her sleep 12 months 24 months and headaches 6MWT (m) 267.3 30.8 20.7 Relatively intact upper limb strength BiPAP overnig

  31. Slide 31: Subject: Female, Mid 60s

    Subject 4 Female, Mid 60’s Initially diagnosed with a limb-girdle muscular dystrophy in late 50’s. Eventually tested for Pompe disease. Change at Change at Baseline Unable to pick up grandchildren and trouble keeping up with her 12 months 24 months husband on walks 6MWT (m) 406.3 33.4 26.4 No BiPAP

  32. Slide 32: Compassionate Access Single Case Review

    Compassionate Access Single Case Review John F. Crowley, Chairman and Chief Executive Officer Markus Peceny, Medical Director

  33. Slide 33: Expanded Access Program (EAP) Request

    Compassionate Access Single Case Review 33 Expanded Access Program (EAP) Request Amicus received the compassionate use request on 24th September 2019 “This is a request for emergency early access to your new acid glucosidase preparation that has a higher amount of mannose-6-phosphate residues and is

  34. Slide 34: EAP Request

    Compassionate Access Single Case Review 34 EAP Request

  35. Slide 35: A Message from the Parents

    Compassionate Access Single Case Review 35 EAP Request A Message from the Parents

  36. Slide 36: EAP Request Granted

    Compassionate Access Single Case Review 36 EAP Request Granted Amicus early access granted on 4th October 2019 “God bless you all for your incredible work and your positive decision. I am sure you have saved a life here!!! THANK YOU!!!!!!!!!!!!!!!!!!!!!!!!!! I am in pediatric metabolic diseases for

  37. Slide 37: Diagnosis, Treatment History and Initiation of AT-GAA

    Compassionate Access Single Case Review 37 Diagnosis, Treatment History and Initiation of AT-GAA IOPD CRIM-negative infant initiated treatment on alglucosidase alfa at 7 months of age; experienced decline in cardiac function even after going to 40mg/week. Improved on AT-GAA • Diagnosis of IOPD Jan 2

  38. Slide 38: Clinical Response to ERT measured via Fractional Shortening

    Compassionate Access Single Case Review 38 Clinical Response to ERT measured via Fractional Shortening (FS) After switching to AT-GAA the fractional shortening improved from unmeasurable to a value of 30-36% after only 2-3 months; motor function improved and supplemental oxygen no longer required

  39. Slide 39: Prof. Marquart's Video Testimony

    Compassionate Access Single Case Review 39 Prof. Marquart’s Video Testimony

  40. Slide 40: Parent Video Testimony

    Compassionate Access Single Case Review 40 Parent Video Testimony

  41. Slide 41: Thank You

    Thank You

Amicus Therapeutics — Technical Presentation (February 2020) on 6ix